Vivek Subbiah: RAS-Targeted Therapies Mark a Landmark Year in Pancreatic Cancer Research
Vivek Subbiah/LinkedIn

Vivek Subbiah: RAS-Targeted Therapies Mark a Landmark Year in Pancreatic Cancer Research

Vivek Subbiah, Director of Early Phase Drug Development Program at NYU Langone Health, shared on LinkedIn:

“Wearing purple tie for Pancreatic Cancer Awareness Day.

A landmark year: the first RAS-targeted therapy approved for pancreatic cancer. Still far to go- but eager to work across all stakeholder groups to tackle this beast, with our novel agents including 100+ KRAS-targeted therapies in different stages of research + we need RAS inhibitors approved in a tissue-agnostic manner across all cancers.

Thanks, Simon C, for making me wear a purple tie and arranging a big celebration in New York!”

Vivek Subbiah: RAS-Targeted Therapies Mark a Landmark Year in Pancreatic Cancer Research

You may also be interested in: